For the subsequent, chronic 6-week oral testing at 15 mg/kg BID (30 mg/kg daily), the 3xTg-AD model was used that expresses human tau with the MAPT P301L mutation in addition to mutations in PS1 and APP, to enable analysis of DDL-357 effects on tau phosphorylation. The gene discussed is MAPT; the disease is Alzheimer disease.